Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
   Home  |  Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only
Print | Text Size:

Resources and Tools

 

Follow-up Care

If you are at an early stage of the disease, where no treatment is necessary, your doctor will see you every few months to monitor your condition and look for any changes that may prompt initiation of treatment.4,10

If you did receive treatment, you will also be monitored regularly to evaluate the effectiveness of your treatment and to look for signs of disease progression. If you do not respond to initial therapy, or if you responded but your CLL begins to progress again, you may be given "second-line therapy." Second-line therapy is typically considered palliative; that is, it is given to relieve symptoms.8

If symptoms of a significant infection occur, such as a high temperature (over 100°F/38°C), you should contact your doctor. (See Avoiding and Treating Infection.)

Infections may occur because the immune system is weakened in CLL.4 Infection is the most common cause of death in patients with CLL.3,10 For some time after treatment, you may continue to take medications such as antibiotics or colony-stimulating factors to prevent bacterial and/or viral infections.4,10 Infections may be treated with antibiotics or antifungal or antiviral agents.4 However, there is much a patient can do to avoid developing serious infections. (See Avoiding and Treating Infection.)

The appearance of a lump or the enlargement of an existing one may be a good reason to ask for an earlier appointment, but the slow rate of development of most cases of CLL means that you probably do not need to see your doctor urgently.

Patients with more advanced disease who have been treated and whose disease is no longer progressing rapidly will also be seen regularly to check if the disease is still in remission.

Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).